Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection
Open Access
- 1 June 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (6) , 1544-1548
- https://doi.org/10.1128/aac.44.6.1544-1548.2000
Abstract
We have correlated the in vitro results of testing the susceptibility of Cryptococcus neoformans to fluconazole with the clinical outcome after fluconazole maintenance therapy in patients with AIDS-associated cryptococcal disease. A total of 28 isolates of C. neoformans from 25 patients (24 AIDS patients) were tested. The MICs were determined by the broth microdilution technique by following the modified guidelines described in National Committee for Clinical Standards (NCCLS) document M27-A, e.g., use of yeast nitrogen base medium and a final inoculum of 10 4 CFU/ml. The fluconazole MIC at which 50% of isolates are inhibited (MIC 50 ) and MIC 90 , obtained spectrophotometrically after 48 h of incubation, were 4 and 16 μg/ml, respectively. Of the 25 patients studied, 4 died of active cryptococcal disease and 2 died of other causes. Therapeutic failure was observed in five patients who were infected with isolates for which fluconazole MICs were ≥16 μg/ml. Four of these patients had previously had oropharyngeal candidiasis (OPC); three had previously had episodes of cryptococcal infection, and all five treatment failure patients had high cryptococcal antigen titers in either serum or cerebrospinal fluid (titers, >1:4,000). Although 14 of the 18 patients who responded to fluconazole therapy had previously had OPC infections, they each had only a single episode of cryptococcal infection. It appears that the clinical outcome after fluconazole maintenance therapy may be better when the infecting C. neoformans strain is inhibited by lower concentrations of fluconazole for eradication (MICs, <16 μg/ml) than when the patients are infected with strains that require higher fluconazole concentrations (MICs, ≥16 μg/ml). These findings also suggest that the MICs determined by the modified NCCLS microdilution method can be potential predictors of the clinical response to fluconazole therapy and may aid in the identification of patients who will not respond to fluconazole therapy.Keywords
This publication has 35 references indexed in Scilit:
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Possible Development of Resistance to Fluconazole During Suppressive Therapy for AIDS-Associated Cryptococcal MeningitisClinical Infectious Diseases, 1996
- Identification of Patients with Acute AIDS-Associated Cryptococcal Meningitis Who Can Be Effectively Treated with Fluconazole: The Role of Antifungal Susceptibility TestingClinical Infectious Diseases, 1996
- Increased Fluconazole Resistance of Cryptococcus neoformans Isolated from a Patient with AIDS and Recurrent MeningitisClinical Infectious Diseases, 1994
- Cryptococcal Meningitis and AIDSClinical Infectious Diseases, 1993
- Management of CryptococcosisClinical Infectious Diseases, 1993
- Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazoleAntimicrobial Agents and Chemotherapy, 1993
- A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Cryptococcal Meningitis in Patients with AIDSThe Journal of Infectious Diseases, 1988
- In-vitro resistance to imidazole antifungals in Candida albicansJournal of Antimicrobial Chemotherapy, 1984